In addition, PPAR agonists, such as bezafibrate and elafibranor, downregulate the expression of bile acid synthase CYP7A1, which is the key regulator of bile acid synthesis, thereby having beneficial effects on PBC in (pre)clinical trials [36,56,66]. This evidence concerns the gene CYP7A1 and primary biliary cholangitis.